RT Journal Article
SR Electronic
T1 Modelling the Test, Trace and Quarantine Strategy to Control the COVID-19 Epidemic in the State of São Paulo, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242743
DO 10.1101/2020.12.02.20242743
A1 Amaku, Marcos
A1 Covas, Dimas Tadeu
A1 Coutinho, Francisco Antonio Bezerra
A1 Azevedo Neto, Raymundo Soares
A1 Struchiner, Claudio
A1 Wilder-Smith, Annelies
A1 Massad, Eduardo
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242743.abstract
AB Testing for detecting the infection by SARS-CoV-2 is the bridge between the lockdown and the opening of society. In this paper we modelled and simulated a test-trace-and-quarantine strategy to control the COVID-19 outbreak in the State of São Paulo, Brasil. The State of São Paulo failed to adopt an effective social distancing strategy, reaching at most 59% in late March and started to relax the measures in late June, dropping to 41% in 08 August. Therefore, São Paulo relies heavily on a massive testing strategy in the attempt to control the epidemic.Two alternative strategies combined with economic evaluations were simulated. One strategy included indiscriminately testing the entire population of the State, reaching more than 40 million people at a maximum cost of 2.25 billion USD, that would reduce the total number of cases by the end of 2020 by 90%. The second strategy investigated testing only symptomatic cases and their immediate contacts – this strategy reached a maximum cost of 150 million USD but also reduced the number of cases by 90%.The conclusion is that if the State of São Paulo had decided to adopt the simulated strategy on April the 1st, it would have been possible to reduce the total number of cases by 90% at a cost of 2.25 billion US dollars for the indiscriminate strategy but at a much smaller cost of 125 million US dollars for the selective testing of symptomatic cases and their contacts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by the project ZikaPLAN, funded by the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 734584, by LIM01-HFMUSP, CNPq and FAPESP and Fundacao Butantan. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval. Not applicable (this is a purely theoretical work with no human subject involved). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data on COVID-19 cases and deaths are available in https://www.seade.gov.br/